Category Archives: Scientific contents

The Cancer Transcriptome Atlas (CTA) is designed for comprehensive profiling of the tumor biology, tumor microenvironment, and the immune response. It covers the RNA expression of over 1,800 genes simultaneously with spatial resolution in any region of interest from a single tissue section.

The CTA assay is compatible with RNAscope® and antibody visualization markers. It can also be supplemented with up to 60 additional targets of interest.

Learn about out spatial transcriptomics services

Comprehensively Annotated Pathways in the CTA

Adaptive Immunity		Cell Function		Signaling Pathways
T cells B cells		Apoptosis		AMPK Signaling
TCR & BCR Signaling		Autophagy		Androgen Signaling
Cancer Antigens		Cell Adhesion & Motility		EGFR Signaling
MHC Class I & II Antigen Presentation		Cell Cycle		ERBB2 Signaling
T-cell Checkpoints		Cilium Assembly		Estrogen Signaling
TH1, TH2, TH9, Th17, and Treg Differentiation		Differentiation		FGFR Signaling
		DNA Damage Repair		FoxO Signaling
Innate Immunity		EMT		GPCR Signaling
Complement System		Endocytosis		Hedgehog Signaling
Dendritic Cells		Epigenetic Modification		HIF1 Signaling
DNA & RNA Sensing		Immortality & Stemness		Insulin Signaling
Glycan Sensing		Ion Transport		JAK-STAT Signaling
Host Defense Peptides		Lysosome		MAPK Signaling
Inflammasomes		Oxidative Stress		MET Signaling
Myeloid Inflammation		Phagocytosis		mTOR Signaling
Neutrophil Degranulation		Proteotoxic Stress		Myc
NK Activity		RNA Processing		NO Signaling
NLR Signaling		Senescence		Notch Signaling
RAGE Signaling				p53 Signaling
TLR Signaling		Metabolism		PDGF Signaling
		Amino Acid Synthesis & Transport		PI3K-Akt Signaling
Immune Response		Arginine & Glutamine Metabolism		PPAR Signaling
Chemokine Signaling		Fatty Acid Oxidation & Synthesis		Purinergic Signaling
Cytotoxicity		Glycolysis & Glucose Transport		Retinoic Acid Signaling
IL-1, IL-2, IL-6 & IL-17 Signaling		Glycosylation		TGF-beta Signaling
Immune Exhaustion		IDH1/2		VEGF Signaling
Interferon Response Genes		Lipid Metabolism		Wnt Signaling
Lymphocyte Regulation & Trafficking		Mitochondrial Metabolism / TCA
NF-kB Signaling		Nucleotide Synthesis		Physiology & Disease
Other Interleukin Signaling		Pentose Phosphate		Angiotensin System
Prostaglandin Inflammation		Tryptophan & Kynurenine Metabolism		Circadian Clock
TNF Signaling		Vitamin & Cofactor Metabolism		Drug Resistance
Type I, II, & III Interferon Signaling				Glioma
				Leukemia
				Matrix Remodeling and Metastasis
				Melanoma
				Neuroendocrine Function
				Prostate Cancer

Soft Tissue Sarcoma (STS) is known to be refractory to current cancer immunotherapies including the PD1 immune checkpoint inhibitor (ICI) (Toulmonde et al., 2018), thus claiming the development of novel therapeutic strategies aiming at improving the current clinical benefit.

Drawing on our expertise in IHC and IHF assays, we have developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets.

Discover why there is a crucial need to decipher mechanisms underlying sensitivity / resistance to cancer immunotherapies which can ultimately lead to the identification of novel therapeutic targets and how to achieve it.

Our data illustrated here through DC differentiation and mixed leukocyte reaction assays show that adenosine-mediated suppression results in the generation of phenotypically and functionally dysregulated DCs, and that this process is relieved by adenosine receptor antagonists.

We have fully set up and characterized a syngeneic Lewis LLC1 mouse model for preclinical studies of novel therapeutic agents and anti-cancer strategies.

In a recent collaborative work (1) supervised by Pr A. Italiano and published in Nature Cancer (2), we highlighted that the presence of mature tertiary lymphoid structures (mTLS) – a structure of prominent B cell follicles and follicular dendritic cells adjoined to a CD4/CD8 T cell-containing zone - is a new predictive biomarker for response for immune checkpoint blockers.

It becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), the Digital Spatial Profiling revolution has started.

To deal with the current challenge of a qualitative and quantitative tumor immune landscape characterization, we have set up a fully integrated platform spanning from FFPE slide preparation and staining, to image digitization and analysis.

Explicyte’s expertise and advanced technologies have been harnessed so as to build a cell-based service platform for immuno-oncology (IO) assessment and drug discovery.

B cells are to the forefront of cancer immunotherapy. Discover how!